Stereotaxis Inc

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stereotaxis anticipates revenue growth in 2023 with key innovations

Stereotaxis is poised for growth with key innovations nearing commercialization and a strong balance sheet.
Strategic collaborations, improved pipeline visibility, and targeted growth strategies position the company for future success.
Challenges in customer engagement and market penetration require proactive strategies to drive revenue growth.
Opportunities in SaaS business spin-off, IDN engagement, and product launches offer avenues for revenue expansion and market presence.

Stereotaxis Inc reports revenue decline but expects growth opportunities

Stereotaxis Inc reports revenue decline but expects growth with Genesis
Positive feedback on technology, regulatory progress, and innovation efforts
Challenges include catheter shortages and financial balancing act
Opportunities lie in increasing system orders and upcoming market releases

Stereotaxis Inc reports robust revenue growth and strategic collaborations

Stereotaxis Inc's Q2 2023 performance showcased strong revenue growth and strategic collaborations driving innovation.
While facing challenges like regulatory delays and cash flow issues, the company is focused on reducing cash usage and advancing key projects.
Opportunities lie in connectivity software releases, product development, and regulatory submissions, positioning Stereotaxis for future growth.

Stereotaxis reports Q3 revenue growth, faces operational challenges

Stereotaxis Inc saw modest revenue growth in Q3 driven by robotic system sales, but faced an operating loss.
Maintaining a strong financial position with no debt provides stability amidst operational challenges.
The company's focus on innovation and market strategies presents opportunities for future growth and product development.

Stereotaxis Inc reports Q4 revenue of $4.6M, focuses on innovation and regulatory progress

Stereotaxis Inc navigated challenges in Q4 2023 with a focus on innovation and strategic transformation. Strong financial position and confidence in regulatory processes position the company well for future growth. Revenue guidance for 2024 indicates potential for stable recurring revenue and increased system revenue.

Stereotaxis reports Q1 revenue growth, innovation progress, and APT acquisition

Stereotaxis Inc's Q1 2024 earnings call highlighted revenue growth, innovation progress, and the acquisition of APT. Despite challenges with recurring revenue and an operating loss, the company is optimistic about future growth driven by system backlog and new orders.

Stereotaxis Inc. reports Q2 loss, anticipates growth from GenesisX shipments

Stereotaxis Inc. faces challenges from reduced capital revenue but shows resilience with stable recurring revenue and a strong gross margin.
The company's strategic initiatives, including GenesisX and the APT acquisition, position it well for future growth and market expansion.
Analysts' inquiries reflect interest in key growth drivers like GenesisX, manufacturing scale-up, and macroeconomic influences on the business.
Overall, Stereotaxis Inc. aims for a stronger second half in 2024, leveraging new product offerings and revenue streams for improved financial performance.

Stereotaxis Inc reports revenue growth in Q3 2024 earnings

Stereotaxis Inc showed solid revenue growth in Q3 2024, driven by system and recurring revenue.
While facing challenges in operating expenses and profitability, the company has opportunities for growth.
Managing expenses and capitalizing on revenue potential could position Stereotaxis for improved financial performance.
The increase in cash reserves also provides a buffer for future investments and operations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

If you are looking for stocks that are well positioned to maintain their recent uptrend, Stereotaxis Inc. (STXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why "Trend" Investors Would Love Betting on Stereotaxis Inc. (STXS)

Stereotaxis, Inc. (NYSE:STXS) produces robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.

Could This Medical Device Stock Be the Next Big Growth Name?

Stereotaxis Inc. (STXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Stereotaxis Inc. (STXS) Soars 10%: Is Further Upside Left in the Stock?

Stereotaxis Inc. (STXS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes Stereotaxis Inc. (STXS) a Good Fit for "Trend Investing"

Stereotaxis, Inc. (STXS) CEO David Fischel on Q1 2021 Results - Earnings Call Transcript

ST. LOUIS, May 10, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021.

Stereotaxis Reports 2021 First Quarter Financial Results

ST. LOUIS, April 19, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 first quarter on Monday, May 10, 2021 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report First Quarter 2021 Financial Results on May 10, 2021

Stereotaxis will emerge from COVID-19 with higher recurring sales due to pent up demand for surgeries and greenfield system sales. The company's new proprietary catheter will increase recurring revenue through vertical integration.

3 Catalysts For Stereotaxis That Have Investors Excited

ST. LOUIS, April 12, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that David Fischel, Chairman and CEO, will serve as the keynote speaker at the Robotic Surgery & Enabling Technologies Virtual Summit 2021. The presentation will take place on Thursday, April 15, 2021.

Stereotaxis CEO Invited as Keynote Speaker at Robotic Surgery & Enabling Technologies Summit 2021

ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Broward Health Medical Center is establishing a robotic electrophysiology program to expand access to advanced minimally-invasive treatment of heart rhythm disorders in Florida. Broward Health Medical Center will be the only hospital in South Florida offering robotic technology to treat patients suffering from arrhythmias and is the first in Florida, and among the first in the nation, to adopt the latest Genesis Robotic Magnetic Navigation system.

Broward Health Medical Center Becomes First Hospital in Florida to Adopt Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders

ABB Ltd.

iRobot

Intuitive Surgical

Revolution Acceleration Acquisition Corp

Robotics stocks should have years of growth ahead as the trend toward automation continues. These 5 names aren't cheap, but look worth paying up for.

5 Robotics Stocks on the Cutting Edge

Stereotaxis Inc. (STXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Stereotaxis Inc. (STXS) Moves 13.6% Higher: Will This Strength Last?

Stereotaxis' (STXS) CEO David Fischel on Q4 2020 Results - Earnings Call Transcript

ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Stereotaxis Reports 2020 Full Year Financial Results

ST. LOUIS, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO performance stock award for David Fischel with vesting entirely contingent upon the company achieving billion-dollar market capitalization milestones.

Stereotaxis Announces Long-Term CEO Performance Stock Award

ST. LOUIS, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript

Stereotaxis, Inc.'s (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript

ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020.

Stereotaxis Reports 2020 Third Quarter Financial Results

ST. LOUIS, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 third quarter on Monday, November 9, 2020 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Third Quarter 2020 Financial Results on November 9, 2020

ST. LOUIS, Sept.  14, 2020  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has completed installations of the world’s first Genesis Robotic Magnetic Navigation (RMN) systems to treat heart rhythm disorders at Helsinki University Hospital in Finland and Banner - University Medicine Heart Institute in Phoenix, Arizona.

First Hospitals in the World Adopt Genesis Robotic Technology for Cardiac Heart Rhythm Disorders

ST. LOUIS, Sept.  08, 2020  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will serve as a panel speaker at the plenary session of RAPS Convergence 2020. RAPS Convergence is the largest annual gathering of regulatory professionals in healthcare and is hosted by the Regulatory Affairs Professionals Society. The plenary session will take place on Sunday, September 13, 2020.

Stereotaxis CEO Invited to Speak on Plenary Panel at RAPS Convergence 2020

ST. LOUIS, Aug.  28, 2020  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at three investor conferences in September 2020.

Stereotaxis to Present at Three Investor Conferences in September

ST. LOUIS, Aug.  26, 2020  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a pioneering publication in the prestigious Journal of the American College of Cardiology (JACC) on the use of Stereotaxis’ robotic technology to treat pulmonary hypertension.

Journal of American College of Cardiology Publishes Pioneering Study Using Stereotaxis Robotic Technology to Treat Pulmonary Hypertension

Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2020 Results - Earnings Call Transcript

News for Stereotaxis Inc Stock (STXS)